{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:27:40Z","timestamp":1787023660862,"version":"build-2736575974"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,7,2]]},"DOI":"10.18632\/oncotarget.28249","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T08:14:01Z","timestamp":1656749641000},"page":"864-875","source":"Crossref","is-referenced-by-count":18,"title":["Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation"],"prefix":"10.18632","volume":"13","author":[{"given":"Raquel","family":"Torres-Guzm\u00e1n","sequence":"first","affiliation":[{"name":"Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Patricia","family":"Ganado","sequence":"additional","affiliation":[{"name":"Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Mur","sequence":"additional","affiliation":[{"name":"Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Marugan","sequence":"additional","affiliation":[{"name":"Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baquero","sequence":"additional","affiliation":[{"name":"Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhu","family":"Yang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Bian","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Du","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"de Dios","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Puig","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Lallena","sequence":"additional","affiliation":[{"name":"Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"13","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"1","author":"Slamon","year":"2016","journal-title":"Breast Cancer Res"},{"key":"3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s0092-8674(00)81519-6","article-title":"Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1","volume":"9","author":"Dean","year":"1999","journal-title":"Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Barbacid","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"1","author":"Turner","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"1","author":"Zhang","year":"2016","journal-title":"Lancet Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"37","author":"Conte","year":"2016","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1200\/JCO.2016.34.15_suppl.510","article-title":"MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+\/HER2-breast cancer, after chemotherapy for advanced disease","volume":"3","author":"Baselga","year":"2016","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"3","author":"Frenzel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"3","author":"Testa","year":"2021","journal-title":"Ann Oncol"},{"key":"11","unstructured":"VERZENIO\u2122 (abemaciclib) [US Package Insert]. In Company ELa (ed). 2021."},{"key":"12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/jjco\/hyz151","article-title":"Differences of cyclin-dependent kinase 4\/6 inhibitor, palbociclib and abemaciclib, in breast cancer","volume":"4","author":"Tamura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-017-0559-8","article-title":"A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients","volume":"5","author":"Cronier","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors","volume":"6","author":"Schade","year":"2016","journal-title":"Cancer Discov"},{"key":"15","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR\/HER2Metastatic Breast Cancer","volume":"2","author":"Baselga","year":"2017","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Goetz","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Conte","year":"2020","journal-title":"JAMA Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"3","author":"Okada","year":"2020","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"Lallena","year":"2017","journal-title":"Oncotarget"},{"key":"20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft","volume":"4","author":"De Dios","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"1","author":"Schwartz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib","volume":"5","author":"Steeghs","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"23","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A Phase I Study of the Cyclin-Dependent Kinase 4\/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas","volume":"2","author":"Shapiro","year":"2016","journal-title":"Clin Cancer Res"},{"key":"24","unstructured":"IBRANCE\n                      \u00ae\n                      [US Package Insert]. In Pfizer INY N (ed). 2016."},{"key":"25","unstructured":"KISQALI\n                      \u00ae\n                      (ribociclib) [US Package Insert]. In Pharmaceuticals N (ed). 2017."},{"key":"26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4\/6 Inhibitors and the Potential for Differential Clinical Activity","volume":"2","author":"Sorger","year":"2019","journal-title":"Cell Chem Biol"},{"key":"27","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","article-title":"Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4\/6 Inhibitor in Various Solid Tumors","volume":"2","author":"Sellers","year":"2017","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","article-title":"CDK6 levels regulate quiescence exit in human hematopoietic stem cells","volume":"1","author":"Dick","year":"2015","journal-title":"Cell Stem Cell"},{"key":"29","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.1128\/MCB.00800-06","article-title":"Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes","volume":"2","author":"Sicinski","year":"2006","journal-title":"Mol Cell Biol"},{"key":"30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ni1324","article-title":"A unique function for cyclin D3 in early B cell development","volume":"7","author":"Aifantis","year":"2006","journal-title":"Nat Immunol"},{"key":"31","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3324\/haematol.2020.256313","article-title":"Inducible deletion of CDK4 and CDK6 - deciphering CDK4\/6 inhibitor effects in the hematopoietic system","volume":"10","author":"Prchal-Murphy","year":"2021","journal-title":"Haematologica"},{"key":"32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"3","author":"Chan","year":"2014","journal-title":"Invest New Drugs"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T08:14:04Z","timestamp":1656749644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7,2]]}},"alternative-id":["28249"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28249","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]}}}